66 related articles for article (PubMed ID: 3007973)
1. [Cytotoxicity of interleukin 2-induced lymphocytes and effects of serum immunosuppressive factors].
Sugiyama Y; Takao H; Umemoto T; Niwa H; Kida H; Saji S; Sakata K
Nihon Geka Gakkai Zasshi; 1986 Jan; 87(1):3-9. PubMed ID: 3007973
[TBL] [Abstract][Full Text] [Related]
2. [Studies on adoptive immunotherapy using recombinant interleukin 2].
Sugiyama Y; Takao H; Saji S; Sakata K
Gan To Kagaku Ryoho; 1986 Apr; 13(4 Pt 2):1307-13. PubMed ID: 3488028
[TBL] [Abstract][Full Text] [Related]
3. [Effects of serum immunosuppressive factors on the cytotoxicity of lymphokine-activated killer (LAK) cells induced by recombinant interleukin 2(R-IL2)].
Takao H; Saji S; Sugiyama Y; Tachibana S; Goshima H; Kunii Y; Sakata K
Nihon Geka Gakkai Zasshi; 1988 Jul; 89(7):992-8. PubMed ID: 2975748
[TBL] [Abstract][Full Text] [Related]
4. Cytotoxicity tests against cultured human lung cancer cells with autologous lymphocytes activated in vitro by mitomycin C-treated tumor monolayers in the presence of T-cell growth factor.
Kimura H; Yamaguchi Y; Kadoyama C; Sato N; Fujisawa T
Jpn J Clin Oncol; 1983 Mar; 13(1):3-13. PubMed ID: 6300483
[TBL] [Abstract][Full Text] [Related]
5. [Observation on natural killer cell activity in gastric cancer patients and effect of nonspecific immunopotentiator administration on its postoperative reduction].
Oshita H; Saji S; Sugiyama Y; Tanemura H; Sakata K; Tanaka S; Ito T
Nihon Geka Gakkai Zasshi; 1985 Oct; 86(10):1417-25. PubMed ID: 4079897
[TBL] [Abstract][Full Text] [Related]
6. Effects of serum immunosuppressive factors on antitumor cytotoxicity of interleukin 2-induced lymphocytes.
Sugiyama Y; Sakata K; Saji S; Takao H; Hamuro J
J Surg Oncol; 1987 Aug; 35(4):223-9. PubMed ID: 3497306
[TBL] [Abstract][Full Text] [Related]
7. Natural killer and lymphokine-activated killer activities in stomach cancer patients with special emphasis on the effect of 5-fluorouracil, adriamycin and mitomycin-C chemotherapy.
Hong WS; Kim CM; Lee JO; Kang TW; Yun TK; Kim CY
Jpn J Clin Oncol; 1990 Mar; 20(1):87-93. PubMed ID: 2108272
[TBL] [Abstract][Full Text] [Related]
8. [Distribution of lymphocyte subpopulation and natural killer activity in gastric cancer tissue, normal stomach and various tissues of gastric cancer patients].
Moritani Y
Nihon Geka Gakkai Zasshi; 1984 Feb; 85(2):132-42. PubMed ID: 6611484
[TBL] [Abstract][Full Text] [Related]
9. Activated killer cell activity of spleen cells from patients with gastric carcinoma.
Akiyoshi T; Koba F; Arinaga S; Tsuji H
J Clin Lab Immunol; 1987 Aug; 23(4):197-201. PubMed ID: 2959788
[TBL] [Abstract][Full Text] [Related]
10. Synergy of tumor necrosis factor and interleukin 2 in the activation of human cytotoxic lymphocytes: effect of tumor necrosis factor alpha and interleukin 2 in the generation of human lymphokine-activated killer cell cytotoxicity.
Owen-Schaub LB; Gutterman JU; Grimm EA
Cancer Res; 1988 Feb; 48(4):788-92. PubMed ID: 3257408
[TBL] [Abstract][Full Text] [Related]
11. Activated alpha 2-macroglobulin reverses the immunosuppressive activity in human breast cancer cell-conditioned medium by selectively neutralizing transforming growth factor-beta in the presence of interleukin-2.
Harthun NL; Weaver AM; Brinckerhoff LH; Deacon DH; Gonias SL; Slingluff CL
J Immunother; 1998 Mar; 21(2):85-94. PubMed ID: 9551359
[TBL] [Abstract][Full Text] [Related]
12. Rapid generation of potent and tumor-specific cytotoxic T lymphocytes by interleukin 18 using dendritic cells and natural killer cells.
Tanaka F; Hashimoto W; Okamura H; Robbins PD; Lotze MT; Tahara H
Cancer Res; 2000 Sep; 60(17):4838-44. PubMed ID: 10987295
[TBL] [Abstract][Full Text] [Related]
13. Fucose-activated killer (FAK) cells: anomalous killers with augmented cytotoxic activity.
Stanková J; Rola-Pleszczynski M
J Immunol; 1985 Dec; 135(6):3719-28. PubMed ID: 2415584
[TBL] [Abstract][Full Text] [Related]
14. Evaluation of different effects of sera of breast cancer patients on the activity of natural killer cells.
Konjević G; Spuzić I
J Clin Lab Immunol; 1992; 38(2):83-93. PubMed ID: 1343351
[TBL] [Abstract][Full Text] [Related]
15. Role of interleukin 2 and a serum suppressive factor on the induction of activated killer cells cytotoxic for autologous human melanoma cells.
Itoh K; Tilden AB; Balch CM
Cancer Res; 1985 Jul; 45(7):3173-8. PubMed ID: 3924397
[TBL] [Abstract][Full Text] [Related]
16. Tumor-draining lymph nodes of primary lung cancer patients: a potent source of tumor-specific killer cells and dendritic cells.
Kimura H; Dobrenkov K; Iida T; Suzuki M; Ando S; Yamamoto N
Anticancer Res; 2005; 25(1A):85-94. PubMed ID: 15816523
[TBL] [Abstract][Full Text] [Related]
17. [Experimental studies on induction of various lymphokine-activated killer cells using recombinant interleukin 2].
Takao H; Saji S; Sugiyama Y; Tachibana S; Goshima H; Morita T; Sakata K
Nihon Geka Gakkai Zasshi; 1988 May; 89(5):646-54. PubMed ID: 3261830
[TBL] [Abstract][Full Text] [Related]
18. Lymphokine-activated killer activity of tumor-associated and peripheral blood lymphocytes isolated from patients with ascites ovarian tumors.
Allavena P; Zanaboni F; Rossini S; Merendino A; Bonazzi C; Vassena L; Mangioni C; Mantovani A
J Natl Cancer Inst; 1986 Oct; 77(4):863-8. PubMed ID: 3489856
[TBL] [Abstract][Full Text] [Related]
19. Cytolysis of mammary tumor targets by resting, interleukin-2 stimulated and in vitro cultured peripheral blood lymphocytes from breast cancer patients.
Brenner BG; McCrea EL; Margolese RG
Anticancer Res; 1988; 8(4):653-8. PubMed ID: 3263077
[TBL] [Abstract][Full Text] [Related]
20. Characteristics of murine non-specific killer cells induced in vivo by recombinant human interleukin-2.
Hinuma S; Naruo K; Shiho O; Tsukamoto K
Immunology; 1986 Oct; 59(2):251-9. PubMed ID: 3490435
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
